title: uCyt+/ImmunoCyt and cytology in the detection of urothelial carcinoma: an update on 7422 analyses.
abstract: BACKGROUND
  The aim of the current study was to report the results of 7422 uCyt+/ImmunoCyt and cytology analyses that were performed over the course of 9 years at the study institution for the evaluation and follow-up of patients with urothelial carcinoma.
  
  
  METHODS
  Between January 2002 and March 2011, 2217 patients with a mean age of 69.5 years (range, 15 years-99 years) were enrolled in the current study. All patients seen for the follow-up of bladder and/or upper tract urothelial cancer as well as those with a history that was suspicious for bladder cancer were recruited. In all patients, a voided urinary cytology and uCyt+/ImmunoCyt test was performed. Patients underwent routine cystoscopy as well as cystoscopy when cytology and/or the uCyt+/ImmunoCyt test yielded positive results. Lesions that were detected cystoscopically were biopsied and removed transurethrally. A total of 7422 uCyt+/ImmunoCyt and cytology analyses were performed.
  
  
  RESULTS
  Of the 7422 uCyt+/ImmunoCyt tests and cytologies that were performed, 7075 (95.3%) were considered adequate. A total of 578 patients (with 1156 analyses) underwent biopsy and 728 (63%) samples had a histologically proven urothelial carcinoma. Overall sensitivity was 34.5% for cytology, 68.1% for uCyt+/ImmunoCyt, and 72.8% for the 2 tests combined. Overall specificity was 97.9% for cytology, 72.3% for uCyt+/ImmunoCyt, and 71.9% for the 2 tests combined. Cytology and the uCyt+/ImmunoCyt test together had an overall sensitivity of 72.8%, with 59% for grade 1, 77% for grade 2, and 90% for grade 3 tumors (according to the 1973 World Health Organization grading classification system).
  
  
  CONCLUSIONS
  On the basis of their 9-year experience, the authors confirm the value of uCyt+/ImmunoCyt and cytology analyses in the follow-up of patients with non-muscle-invasive urothelial cancer. This could potentially reduce the number and cost of routine cystoscopic examinations in patients who are followed for bladder carcinoma. Cancer (Cancer Cytopathol) 2013;121:392-397. © 2013 American Cancer Society.
authors.affiliation: Department of Urology, Central Hospital of Bolzano, Bolzano, Italy. complojevi94@yahoo.de
authors.forename: Evi
authors.initials: E
authors.lastname: Comploj
authors.forename: Christine
authors.initials: C
authors.lastname: Mian
authors.forename: Andrea
authors.initials: A
authors.lastname: Ambrosini-Spaltro
authors.forename: Christopher
authors.initials: C
authors.lastname: Dechet
authors.forename: Salvatore
authors.initials: S
authors.lastname: Palermo
authors.forename: Emanuela
authors.initials: E
authors.lastname: Trenti
authors.forename: Michele
authors.initials: M
authors.lastname: Lodde
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Horninger
authors.forename: Armin
authors.initials: A
authors.lastname: Pycha
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal; D003558:Cystoscopy; D003581:Cytodiagnosis; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007124:Immunoenzyme Techniques; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D011379:Prognosis; D001749:Urinary Bladder Neoplasms / Q000175:diagnosis* / Q000652:urine; D014556:Urine / Q000166:cytology*; D055815:Young Adult
chemical_list: D000911:Antibodies, Monoclonal
keywords: analyses; cytology; sensitivity; uCyt+/ImmunoCyt test; urothelial carcinoma